Compounds > propyromazine
Page last updated: 2024-12-06

propyromazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Propyromazine is a phenothiazine derivative that has been studied for its potential therapeutic effects as an antipsychotic, antiemetic, and antihistamine. It is synthesized through a multi-step process involving the reaction of phenothiazine with various chemical reagents. Propyromazine exhibits antipsychotic activity through its blockade of dopamine receptors in the brain. However, its clinical use has been limited due to its potential for side effects such as extrapyramidal symptoms, sedation, and cardiovascular issues. Despite its limited clinical application, propyromazine continues to be studied for its potential in treating nausea and vomiting associated with chemotherapy and surgery. Research efforts are ongoing to optimize its pharmacological profile and mitigate potential side effects.'

propyromazine: parent cpd not in Chemline 10/4/82; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

propyromazine : A racemate comprising equimolar amounts of (R)- and (S)-propyromazine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

propyromazine bromide : An organic bromide salt of propyromazine. It is a muscarinic antagonist which has antispasmodic potential. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID71493
CHEMBL ID2105379
CHEBI ID145672
SCHEMBL ID26291
MeSH IDM0053471

Synonyms (47)

Synonym
propyromazine bromide [inn]
einecs 205-657-9
pyrrolidinium, 1-methyl-1-(1-(10-phenothiazinylcarbonyl)ethyl)-, bromide
bromuro de propiromazina [inn-spanish]
bromure de propyromazine [inn-french]
1-methyl-1-(1-(10-phenothiazinylcarbonyl)ethyl)pyrrolidinium bromide
1-methyl-1-(1-phenothiazin-10-ylcarbonylethyl)pyrrolidinium bromide
propyromazini bromidum [inn-latin]
pyrrolidinium, 1-methyl-1-(1-methyl-2-oxo-2-(10h-phenothiazin-10-yl)ethyl)-, bromide
nsc 169416
diamant
145-54-0
propyromazine
diaspasmol
nsc-169416
ld 335
nsc169416
propyromazine bromide
sd 104
pyrrolidinopropionylphenothiazine brommethylate
diospasmyl
sd 104.19
diaspasmyl
sd-104
propyromazini bromidum
bromure de propyromazine
1-methyl-1-[1-oxo-1-(10h-phenothiazin-10-yl)propan-2-yl]pyrrolidinium bromide
1-methyl-1-[1-oxo-1-(10h-phenothiazin-10-yl)propan-2-yl]pyrrolidin-1-ium bromide
rac-1-methyl-1-[1-oxo-1-(10h-phenothiazin-10-yl)propan-2-yl]pyrrolidinium bromide
CHEBI:145672
sd-104-19
bromuro de propiromazina
unii-g69033j83v
g69033j83v ,
ld-335
CHEMBL2105379
sd-104.19
SCHEMBL26291
propyromazine [mi]
pyrrolidinium, 1-methyl-1-(1-methyl-2-oxo-2-(10h-phenothiazin-10-yl)ethyl)-, bromide (1:1)
propyromazine bromide [who-dd]
propyromazine bromide [mart.]
1-methyl-1-(1-oxo-1-(10h-phenothiazin-10-yl)propan-2-yl)pyrrolidin-1-ium bromide
ld 335; nsc 169416; propyromazine bromide; sd 104
Q27278832
2-(1-methylpyrrolidin-1-ium-1-yl)-1-phenothiazin-10-ylpropan-1-one;bromide
AKOS040753633
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
muscarinic antagonistA drug that binds to but does not activate muscarinic cholinergic receptors, thereby blocking the actions of endogenous acetylcholine or exogenous agonists.
antispasmodic drugA drug that suppresses spasms. These are usually caused by smooth muscle contraction, especially in tubular organs. The effect is to prevent spasms of the stomach, intestine or urinary bladder.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
quaternary ammonium saltDerivatives of ammonium compounds, (NH4(+))Y(-), in which all four of the hydrogens bonded to nitrogen have been replaced with univalent (usually organyl) groups.
organic bromide salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.74 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
phenothiazine
10H-phenothiazine : The 10H-tautomer of phenothiazine.		1.9310phenothiazineferroptosis inhibitor;
plant metabolite;
radical scavenger
ConditionIndicatedRelationship StrengthStudiesTrials
Gallstone Disease
[description not available]		01.9310
Acute Edematous Pancreatitis
[description not available]		01.9310
Gallbladder Dyskinesia
[description not available]		01.9310
Biliary Dyskinesia
A motility disorder characterized by biliary COLIC, absence of GALLSTONES, and an abnormal GALLBLADDER ejection fraction. It is caused by gallbladder dyskinesia and/or SPHINCTER OF ODDI DYSFUNCTION.		01.9310
Cholelithiasis
Presence or formation of GALLSTONES in the BILIARY TRACT, usually in the gallbladder (CHOLECYSTOLITHIASIS) or the common bile duct (CHOLEDOCHOLITHIASIS).		01.9310
Colitis
Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.		07.3420
Pancreatitis
INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.		01.9310
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.3420
Pernicious Vomiting of Pregnancy
[description not available]		01.9310
Complications, Pregnancy
[description not available]		01.9310
Muscle Spasm
[description not available]		01.9310
Puerperal Disorders
Disorders or diseases associated with PUERPERIUM, the six-to-eight-week period immediately after PARTURITION in humans.		01.9310
Dystocia
Slow or difficult OBSTETRIC LABOR or CHILDBIRTH.		01.9310
Hyperemesis Gravidarum
Intractable VOMITING that develops in early PREGNANCY and persists. This can lead to DEHYDRATION and WEIGHT LOSS.		01.9310
Spasm
An involuntary contraction of a muscle or group of muscles. Spasms may involve SKELETAL MUSCLE or SMOOTH MUSCLE.		01.9310
Bedwetting
[description not available]		01.9410
Emesis
[description not available]		01.9410
Diarrhea
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.		01.9410
Enuresis
Involuntary discharge of URINE after expected age of completed development of urinary control. This can happen during the daytime (DIURNAL ENURESIS) while one is awake or during sleep (NOCTURNAL ENURESIS). Enuresis can be in children or in adults (as persistent primary enuresis and secondary adult-onset enuresis).		06.9410
Vomiting
The forcible expulsion of the contents of the STOMACH through the MOUTH.		01.9410
Nocturnal Enuresis
Involuntary discharge of URINE during sleep at night after expected age of completed development of urinary control.		01.9410
Colonic Diseases
Pathological processes in the COLON region of the large intestine (INTESTINE, LARGE).		01.9410
Colonic Diseases, Functional
Chronic or recurrent colonic disorders without an identifiable structural or biochemical explanation. The widely recognized IRRITABLE BOWEL SYNDROME falls into this category.		01.9410
Dysentery
Acute inflammation of the intestine associated with infectious DIARRHEA of various etiologies, generally acquired by eating contaminated food containing TOXINS, BIOLOGICAL derived from BACTERIA or other microorganisms. Dysentery is characterized initially by watery FECES then by bloody mucoid stools. It is often associated with ABDOMINAL PAIN; FEVER; and DEHYDRATION.		01.9410
Amebiasis, Intestinal
[description not available]		01.9410